Stereotaxis
Missouri, United States · Information Technology · 50 employees
Stereotaxis develops robotic cardiology instrument navigation systems that enhances the treatment of arrhythmias and coronary diseases.
Funding history
- Funding Round — $3.0M — Aug 2024
- Funding Round — $24.0M — Oct 2016
Recent signals
- Apr 15, 2026: Acquired Stereotaxis Acquires Robocath for Innovative Robotic Technology
- Apr 14, 2026: SEC 8-K (1.01): On April 14, 2026, Stereotaxis, Inc. entered into a Share Sale Agreement to acquire 100% of the share capital and voting power of Robocath, a French company specializing in robotic technology for interventional cardiology and neurointerventions. The acquisition involves the purchase of shares and other securities from Robocath's sellers and an associated manager. This transaction is subject to various closing conditions, indicating a strategic expansion for Stereotaxis into the robotic medical technology sector. The expected impact of this acquisition is significant as it diversifies Stereotaxis's offerings in the healthcare technology market.
- Nov 20, 2024: Launched Stereotaxis Launches Genesis Robotic System at Hospital da Luz in Portugal for Advanced Cardiac Care
- Aug 15, 2024: Raised $3.0M
- Oct 05, 2016: Raised $24.0M
See plans & pricing → Track Stereotaxis’s funding, hiring, and signals — with verified contacts — on Fundz.